MoneyWorks4Me

Sun Pharma concludes acquisition of 100% stake in OTS

16 Dec 2016 Evaluate

Sun Pharmaceutical Industries has successfully concluded the acquisition of 100% stake of Ocular Technologies, Sarl (OTS), a portfolio company of Auven Therapeutics (Auven), on December 15, 2016. OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution).

Earlier in October, the pharma major had executed definitive agreements through its wholly owned subsidiary for the acquisition of 100% of OTS, a portfolio company of Auven, an international private equity company focused on accelerated development of breakthrough therapeutic drugs.

Sun Pharmaceutical Industries is a pharmaceuticals company. The company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API).


Sun Pharma. Inds. Share Price

1899.00 -5.00 (-0.26%)
04-Sep-2026 15:36 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.00
Dr. Reddys Labs. 1154.00
Cipla 1385.00
Lupin 2111.00
Zydus Lifesciences 1121.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: